PE20241892A1 - Inhibidores de la ras - Google Patents
Inhibidores de la rasInfo
- Publication number
- PE20241892A1 PE20241892A1 PE2024001555A PE2024001555A PE20241892A1 PE 20241892 A1 PE20241892 A1 PE 20241892A1 PE 2024001555 A PE2024001555 A PE 2024001555A PE 2024001555 A PE2024001555 A PE 2024001555A PE 20241892 A1 PE20241892 A1 PE 20241892A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- membered
- alkyl
- heteroalkyl
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298098P | 2022-01-10 | 2022-01-10 | |
| PCT/US2023/060288 WO2023133543A1 (en) | 2022-01-10 | 2023-01-09 | Ras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241892A1 true PE20241892A1 (es) | 2024-09-19 |
Family
ID=85199574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001555A PE20241892A1 (es) | 2022-01-10 | 2023-01-09 | Inhibidores de la ras |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250197423A1 (https=) |
| EP (1) | EP4463231A1 (https=) |
| JP (1) | JP2025503641A (https=) |
| KR (1) | KR20240132492A (https=) |
| CN (2) | CN118922423A (https=) |
| AR (1) | AR128234A1 (https=) |
| AU (1) | AU2023204824A1 (https=) |
| CA (1) | CA3246887A1 (https=) |
| CL (2) | CL2024002041A1 (https=) |
| CO (1) | CO2024010814A2 (https=) |
| CR (1) | CR20240276A (https=) |
| IL (1) | IL314033A (https=) |
| MX (1) | MX2024008561A (https=) |
| PE (1) | PE20241892A1 (https=) |
| TW (1) | TW202330553A (https=) |
| WO (1) | WO2023133543A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| JP2025525315A (ja) * | 2022-07-08 | 2025-08-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｋｒａｓ阻害剤として有用な大員環化合物 |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN118047797A (zh) * | 2022-11-16 | 2024-05-17 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AR134354A1 (es) * | 2023-11-16 | 2026-01-07 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento del cáncer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025213065A1 (en) * | 2024-04-05 | 2025-10-09 | Revolution Medicines, Inc. | Peptide conjugates |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) * | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| AU2020377925A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022217053A1 (en) * | 2021-04-09 | 2022-10-13 | Revolution Medicines, Inc. | Use of sos1 inhibitors with ras inhibitors to treat cancers |
| TW202309052A (zh) * | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| AU2022281343A1 (en) * | 2021-05-25 | 2023-11-30 | Revolution Medicines, Inc. | Methods for inhibiting ras |
-
2023
- 2023-01-09 CN CN202380026429.5A patent/CN118922423A/zh active Pending
- 2023-01-09 WO PCT/US2023/060288 patent/WO2023133543A1/en not_active Ceased
- 2023-01-09 TW TW112100804A patent/TW202330553A/zh unknown
- 2023-01-09 EP EP23704026.6A patent/EP4463231A1/en active Pending
- 2023-01-09 MX MX2024008561A patent/MX2024008561A/es unknown
- 2023-01-09 AR ARP230100052A patent/AR128234A1/es unknown
- 2023-01-09 CA CA3246887A patent/CA3246887A1/en active Pending
- 2023-01-09 IL IL314033A patent/IL314033A/en unknown
- 2023-01-09 PE PE2024001555A patent/PE20241892A1/es unknown
- 2023-01-09 KR KR1020247026507A patent/KR20240132492A/ko active Pending
- 2023-01-09 AU AU2023204824A patent/AU2023204824A1/en active Pending
- 2023-01-09 JP JP2024541159A patent/JP2025503641A/ja active Pending
- 2023-01-09 CN CN202411889987.7A patent/CN119798279A/zh active Pending
- 2023-01-09 CR CR20240276A patent/CR20240276A/es unknown
-
2024
- 2024-07-04 CL CL2024002041A patent/CL2024002041A1/es unknown
- 2024-07-10 US US18/769,009 patent/US20250197423A1/en active Pending
- 2024-08-08 CO CONC2024/0010814A patent/CO2024010814A2/es unknown
-
2025
- 2025-03-28 CL CL2025000954A patent/CL2025000954A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024008561A (es) | 2024-07-22 |
| WO2023133543A1 (en) | 2023-07-13 |
| CR20240276A (es) | 2024-08-23 |
| JP2025503641A (ja) | 2025-02-04 |
| KR20240132492A (ko) | 2024-09-03 |
| IL314033A (en) | 2024-09-01 |
| US20250197423A1 (en) | 2025-06-19 |
| CA3246887A1 (en) | 2023-07-13 |
| CN118922423A (zh) | 2024-11-08 |
| CO2024010814A2 (es) | 2024-08-20 |
| AR128234A1 (es) | 2024-04-10 |
| TW202330553A (zh) | 2023-08-01 |
| AU2023204824A1 (en) | 2024-07-18 |
| CL2025000954A1 (es) | 2025-08-01 |
| EP4463231A1 (en) | 2024-11-20 |
| CN119798279A (zh) | 2025-04-11 |
| CL2024002041A1 (es) | 2024-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241892A1 (es) | Inhibidores de la ras | |
| PE20240088A1 (es) | Inhibidores de ras | |
| PE20252777A1 (es) | Inhibidores macrociclicos de ras | |
| PE20240089A1 (es) | Inhibidores de ras para el tratamiento del cancer | |
| PE20241476A1 (es) | Inhibidores de la ras | |
| CO2025015474A2 (es) | Inhibidores macrocíclicos de ras | |
| ECSP22012347A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| CR20250550A (es) | Inhibidores ras. | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| AR041347A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| BR112022003152A2 (pt) | Compostos farmacêuticos | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR116771A1 (es) | Los neuroesteroides activos y sus métodos de uso | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
| CL2025000240A1 (es) | Inhibidores de acc novedosos | |
| BR112021023967A2 (pt) | Compostos tricíclicos | |
| CL2023002722A1 (es) | Derivados de morfolinas sustituidas y usos de estos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR036092A1 (es) | Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende | |
| CO2025013218A2 (es) | Derivados de morfolinas sustituidas y usos de estas | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam |